Should I buy or sell Ascendis Pharma A/S stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ASND shares. View ASND analyst ratings or view top-rated stocks .

What is Ascendis Pharma A/S's stock price target for 2024?

8 brokers have issued 12-month price objectives for Ascendis Pharma A/S's stock. Their ASND share price targets range from $113.00 to $260.00. On average, they anticipate the company's stock price to reach $173.25 in the next year. This suggests a possible upside of 19.3% from the stock's current price. View analysts price targets for ASND or view top-rated stocks among Wall Street analysts .

How have ASND shares performed in 2024?

Ascendis Pharma A/S's stock was trading at $125.95 at the start of the year. Since then, ASND stock has increased by 15.3% and is now trading at $145.23. View the best growth stocks for 2024 here .

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,350,000 shares, an increase of 13.9% from the March 15th total of 2,940,000 shares. Based on an average daily trading volume, of 375,400 shares, the days-to-cover ratio is currently 8.9 days. View Ascendis Pharma A/S's Short Interest .

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our ASND earnings forecast .

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.15) by $0.49. The biotechnology company had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 16,574.15% and a negative net margin of 180.61%.

What ETFs hold Ascendis Pharma A/S's stock?

ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI) , Putnam BioRevolution ETF (SYNB) , Virtus LifeSci Biotech Products ETF (BBP) , BNY Mellon Innovators ETF (BKIV) , Harbor Disruptive Innovation ETF (INNO) , Global X Guru Index ETF (GURU) , Fidelity Disruptive Medicine ETF (FMED) and Simplify Health Care ETF (PINK) .

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV) , Alexion Pharmaceuticals (ALXN) , Neurocrine Biosciences (NBIX) , ACADIA Pharmaceuticals (ACAD) , BioMarin Pharmaceutical (bmrn) , Gilead Sciences (GILD) , Incyte (INCY) , Exelixis (EXEL) , GW Pharmaceuticals (GWPH) and NVIDIA (NVDA) .

When did Ascendis Pharma A/S IPO?

Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by many different institutional and retail investors. Top institutional investors include GAMMA Investing LLC (0.00%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free ASND Stock Alerts

$145.23

-0.81 (-0.55%)

(As of 04/15/2024 ET)

Compare

Today's Range: $145.00
▼
$150.11
50-Day Range: $139.25
▼
$159.40
52-Week Range: $66.03
▼
$161.00

Volume: 379,111 shs
Average Volume: 378,047 shs
Market Capitalization: $8.46 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $173.25

Get Ascendis Pharma A/S alerts:

Ascendis Pharma A/S MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 19.3% Upside
$173.25 Price Target
Short Interest: Bearish
5.75% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.76
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.18) to ($0.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars

Medical Sector

770th out of 929 stocks

Pharmaceutical Preparations Industry

352nd out of 422 stocks

3.4

Analyst's Opinion

Consensus Rating
Ascendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Ascendis Pharma A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.75% of the outstanding shares of Ascendis Pharma A/S have been sold short.
Short Interest Ratio / Days to Cover
Ascendis Pharma A/S has a short interest ratio ("days to cover") of 8.9.
Change versus previous month
Short interest in Ascendis Pharma A/S has recently increased by 13.95%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ascendis Pharma A/S does not currently pay a dividend.
Dividend Growth
Ascendis Pharma A/S does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ASND.

2.6

News and Social Media Coverage

News Sentiment
Ascendis Pharma A/S has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Ascendis Pharma A/S this week, compared to 4 articles on an average week.
Search Interest
Only 2 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.18) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ascendis Pharma A/S is -15.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ascendis Pharma A/S is -15.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Ascendis Pharma A/S Stock (NASDAQ:ASND)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASND Stock News Headlines

April 12, 2024 | benzinga.com

Ascendis Pharma's Options Frenzy: What You Need to Know

April 9, 2024 | americanbankingnews.com

Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of "Moderate Buy" by Analysts

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

April 7, 2024 | seekingalpha.com

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion

April 4, 2024 | benzinga.com

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

April 2, 2024 | msn.com

Roivant announces $1.5B share buyback, positive Phase 2 data

April 2, 2024 | finance.yahoo.com

Biotech With 520% Sales Growth Nears Next Buy Point

March 22, 2024 | finance.yahoo.com

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 22, 2024 | finance.yahoo.com

Two Health Care Stocks Outperform S&P 500, Offer Entries

March 22, 2024 | finance.yahoo.com

Ascendis Pharma A/S (ASND) Rose on Positive Trial Results

March 15, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Ascendis Pharma Amid Favorable Market Dynamics and Strong TransCon PTH Outlook

March 14, 2024 | msn.com

Aurobindo Pharma restarts aseptic product distribution; shares trade higher

March 7, 2024 | finance.yahoo.com

Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4

March 4, 2024 | globenewswire.com

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

February 27, 2024 | morningstar.com

Ascendis Pharma A/S ADR

February 25, 2024 | benzinga.com

$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today

February 22, 2024 | money.usnews.com

Ascendis Pharma A/S - ADR

February 15, 2024 | finance.yahoo.com

Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?

February 15, 2024 | msn.com

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

February 15, 2024 | finance.yahoo.com

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

February 13, 2024 | benzinga.com

How Is The Market Feeling About Ascendis Pharma?

February 10, 2024 | finance.yahoo.com

US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results

February 9, 2024 | msn.com

Ascendis Pharma A/S Is Worried About This – Should You Be Worried Too?

February 8, 2024 | realmoney.thestreet.com

Ascendis Pharma price target raised by $18 at Wedbush, here's why

February 8, 2024 | markets.businessinsider.com

Ascendis Pharma: Strong Buy on Robust Sales and Innovative Pipeline

See More Headlines

Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/07/2024
Today: 4/15/2024
Next Earnings (Estimated): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ASND
CUSIP: N/A
CIK: 1612042
Web: www.ascendispharma.com
Phone: (457) 022-2244
Fax: 45-3694-4010
Employees: 879
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $173.25
High Stock Price Target: $260.00
Low Stock Price Target: $113.00
Potential Upside/Downside: +19.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-521,070,000.00
Net Margins: -180.61%
Pretax Margin: -177.77%
Return on Equity: -16,574.15%
Return on Assets: -55.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.56
Quick Ratio: 2.50

Sales & Book Value

Annual Sales: $288.08 million
Price / Sales: 29.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.73) per share
Price / Book: -53.20

Miscellaneous

Outstanding Shares: 58,220,000
Free Float: 34,934,000
Market Cap: $8.46 billion
Optionable: Optionable
Beta: 0.50

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Jan Moller Mikkelsen (Age 64)
President, CEO, Member of Executive Board & Executive Director
Mr. Scott T. Smith (Age 50)
CFO, Executive VP & Member of Executive Board
Ms. Lotte Sonderbjerg (Age 63)
Executive VP, Chief Administrative Officer & Member of the Executive Board
Mr. Michael Wolff Jensen L.L.M. (Age 53)
Executive VP, Chief Legal Officer & Member of the Executive Board
Mr. Mads Bodenhoff
Senior VP of Finance & Principal Accounting Officer
Mr. Timothy J. Lee
Senior Director of Investor Relations
Mr. Flemming Steen Jensen (Age 63)
Executive Vice President of Product Supply & Quality
Dr. Kennett Sprogoe Ph.D. (Age 45)
Executive VP and Head of Research & Product Development
Dr. Stina Singel M.D. (Age 50)
Ph.D., Executive VP & Head of Clinical Development for Oncology
Mr. Joseph Kelly (Age 55)
Head of U.S. Commercial of Endocrinology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ASND Stock Analysis - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ASND shares.
View ASND analyst ratings or view top-rated stocks.
What is Ascendis Pharma A/S's stock price target for 2024?: 8 brokers have issued 12-month price objectives for Ascendis Pharma A/S's stock. Their ASND share price targets range from $113.00 to $260.00. On average, they anticipate the company's stock price to reach $173.25 in the next year. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for ASND or view top-rated stocks among Wall Street analysts.
How have ASND shares performed in 2024?: Ascendis Pharma A/S's stock was trading at $125.95 at the start of the year. Since then, ASND stock has increased by 15.3% and is now trading at $145.23.
View the best growth stocks for 2024 here.
Are investors shorting Ascendis Pharma A/S?: Ascendis Pharma A/S saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,350,000 shares, an increase of 13.9% from the March 15th total of 2,940,000 shares. Based on an average daily trading volume, of 375,400 shares, the days-to-cover ratio is currently 8.9 days.
View Ascendis Pharma A/S's Short Interest.
When is Ascendis Pharma A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ASND earnings forecast.
How were Ascendis Pharma A/S's earnings last quarter?: Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.15) by $0.49. The biotechnology company had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 16,574.15% and a negative net margin of 180.61%.

What ETFs hold Ascendis Pharma A/S's stock?: ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Virtus LifeSci Biotech Products ETF (BBP), BNY Mellon Innovators ETF (BKIV), Harbor Disruptive Innovation ETF (INNO), Global X Guru Index ETF (GURU), Fidelity Disruptive Medicine ETF (FMED) and Simplify Health Care ETF (PINK).
What other stocks do shareholders of Ascendis Pharma A/S own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).
When did Ascendis Pharma A/S IPO?: Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.
Who are Ascendis Pharma A/S's major shareholders?: Ascendis Pharma A/S's stock is owned by many different institutional and retail investors. Top institutional investors include GAMMA Investing LLC (0.00%).
How do I buy shares of Ascendis Pharma A/S?: Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASND) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Ascendis Pharma A/S MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ascendis Pharma A/S Stock (NASDAQ:ASND)

ASND Stock Price History

ASND Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ASND Stock Analysis - Frequently Asked Questions

Overall MarketRank^™